**Table 3 – Sensitivity analyses: relative incidence in at-risk period versus control period of all outcomes for Zostavax with and without concomitant vaccines and considering all events or first events only**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All vaccines modelled together, for all events** | **Vaccines modelled independently (concomitantly vaccines excluded), for all events** | **All vaccines modelled together, for first events only** | **Vaccines modelled independently (concomitantly vaccines excluded), for first events only** |
|  | **RI (95% CI)** | **RI (95% CI)** | **RI (95% CI)** | **RI (95% CI)** |
| **Injection site reaction** | 77.39 (48.06, 124.62) | 60.54 (37.43, 97.91) | 71.18 (43.64, 116.10) | 57.27 (34.80, 94.25) |
| **Burn** | 1.23 (0.97, 1.57) | 1.12 (0.86, 1.47) | 1.08 (0.78, 1.50) | 1.12 (0.80, 1.58) |
| **Myocardial infarction** | 0.74 (0.41, 1.33) | 0.70 (0.35, 1.36) | 0.90 (0.49, 1.66) | 0.80 (0.39, 1.64) |
| **Stroke** | 0.58 (0.44, 0.78) | 0.51 (0.37, 0.71) | 0.54 (0.37, 0.77) | 0.51 (0.34, 0.76) |
| **Any rash** | 0.97 (0.88, 1.08) | 0.96 (0.86, 1.07) | 1.01 (0.90, 1.14) | 1.01 (0.89, 1.14) |
| **Rash with antiviral** | 0. 83 (0.62, 1.10) | 0.67 (0.49, 0.92) | 0.80 (0.59, 1.09) | 0.64 (0.45, 0.90) |
| **Clinical attendance** | 1.23 (0.97, 1.57) | 0.94 (0.93, 0.94) | NA | NA |

CI: Confidence interval, RI: Relative incidence.